Acacia Research -- CombiMatrix Stock and Acacia Research -- Acacia Technologies Stock Commence Trading On Nasdaq.Business Editors & Health/Medical Writers BIOWIRE2K NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Dec. 16, 2002 Acacia Research Corporation announced today that its two new classes of common stock, Acacia Research -- CombiMatrix (Nasdaq:CBMX) and Acacia Research -- Acacia Technologies (Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator ), have commenced trading on the Nasdaq stock market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. . The two new classes of common stock were created as a result of Acacia's recapitalization that was recently approved by the company's stockholders. The two new classes of stock replace Acacia's common stock that formerly traded on the Nasdaq stock market under the symbol ACRI. Acacia Research -- CombiMatrix stock is intended to reflect the performance of its subsidiary, CombiMatrix Corporation, and Acacia Research -- Acacia Technologies stock is intended to reflect the performance of Acacia Research's media technology businesses. The Acacia Research -- CombiMatrix stock and the Acacia Research -- Acacia Technologies stock are both classes of common stock of Acacia Research and are not stock issued by the respective groups. About Acacia Research Corporation Acacia Research Corporation comprises two operating groups. The Acacia Technologies group consists of our media technology business that licenses its V-chip technology to television manufacturers, and owns pioneering Digital Media Transmission ("DMT See DSL. ") technology. DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. The CombiMatrix group, consisting of our wholly-owned subsidiary CombiMatrix Corporation, is developing a platform technology that has a wide range of applications, from DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics to immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. The platform allows the company to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The company is designing its products principally to be responsive to the needs of pharmaceutical, biotechnology, and academic researchers in analyzing raw genomic data in the discovery and development of pharmaceutical products. Information about Acacia Research Corporation is available at www.acaciaresearch.com. Information about CombiMatrix Corporation is available at www.combimatrix.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion